查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1735638

带状疱疹疫苗市场，2026-2032：依产品类型、疫苗类型、通路、年龄层和地区划分

Zoster Vaccine Market By Product Type (Zostavax, Shingrix), Vaccine Type (Live Attenuated Vaccine, Recombinant Vaccine), Distribution Channel (Hospital Pharmacy, Retail Pharmacy), Age Group (Above 50 to 65 Age, Above 65 Age), & Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

带状疱疹疫苗市场评估-2026-2032

慢性病盛行率的上升和人口老化正在推动带状疱疹疫苗的需求。此外，人们越来越意识到接种疫苗有助于预防由水痘带状疱疹病毒引起的带状疱疹，预计将推动带状疱疹疫苗市场的发展。预计2024年带状疱疹疫苗的销售额将超过16.2亿美元，到2032年将达到34.7亿美元。

此外，疫苗技术的发展和新型更有效疫苗的开发也有望推动带状疱疹疫苗市场的成长。已开发国家医疗政策的持续实施，使该市场在 2026 年至 2032 年期间的复合年增长率达到约 10%。

带状疱疹疫苗市场定义/概述

带状疱疹疫苗，通常称为带状疱疹疫苗，是预防带状疱疹的重要措施。带状疱疹是由水痘带状疱疹病毒重新运作引起的，这种病毒也会导致水痘。该疫苗含有减毒病毒，可刺激免疫系统产生抗体，进而预防或减轻带状疱疹的严重程度。该疫苗的主要用途是预防50岁以上人口的带状疱疹，这些人随着老龄化，免疫力会逐渐减弱，因此患病风险会增加。此外，该疫苗还有助于减少与带状疱疹相关的併发症，例如慢性疼痛和神经系统问题。

目前，带状疱疹疫苗主要有两种：Shingrix 和 Zostavax，进一步的研究正在探索更有效、更广泛应用的疫苗选择。目前正在努力提高全球，特别是中低收入国家的带状疱疹疫苗可及性，以减轻全球带状疱疹相关疾病的负担。

全球带状疱疹患者的增加是否会推动带状疱疹疫苗市场的成长？

由于人口老化、免疫力减弱以及癌症和爱滋病毒等慢性疾病盛行率增加等因素，全球带状疱疹的盛行率正在上升，这将推动带状疱疹疫苗市场的成长。

因此，随着越来越多人意识到接种疫苗的预防带状疱疹的重要性，未来几年带状疱疹疫苗的需求可能会增加。这为带状疱疹疫苗市场的成长带来了巨大的机会。例如，葛兰素史克于2023年4月25日推出了一款带状疱疹疫苗（Zoster）。据葛兰素史克称，该疫苗的有效率为90%，可提供至少10年的带状疱疹保护期。

人们越来越意识到接种疫苗对预防带状疱疹的重要性，这推动了带状疱疹疫苗市场的需求。全球人口老化也促进了市场的成长，因为老年人更容易感染带状疱疹。例如，一项针对印度人口的血清流行率研究表明，到40岁时，超过90%的参与者体内持有病毒，这使得他们更容易感染带状疱疹。为了预防带状疱疹和带状疱疹后遗症神经痛， 定序疫苗已核准用于50岁及以上成年人。

此外，疫苗技术的进步以及新型、更有效疫苗的研发预计将推动市场成长。所有这些因素预计将推动带状疱疹疫苗市场在未来几年稳步成长。

带状疱疹疫苗的高成本是否会阻碍带状疱疹疫苗市场的成长？

带状疱疹疫苗的高成本是许多人（尤其是在低收入国家）接种疫苗的一大障碍，并可能阻碍带状疱疹疫苗市场的成长。造成此成本障碍的因素很多，包括研发的复杂性、生产流程、配送物流，以及需要多次接种才能确保有效免疫。

此外，医疗保健提供者和医疗机构在购买带状疱疹疫苗等高成本疫苗时可能面临财务限制，尤其是在报销率较低的环境中，这可能会进一步限制获得疫苗接种的机会，减少整体需求并限制市场成长。

人们日益意识到严格的监管规定，这无疑会对带状疱疹疫苗市场的成长构成挑战。疫苗核准流程冗长且成本高昂，这可能会延迟新疫苗的上市，并限制其供应。此外，严格的安全性和有效性监管要求可能会使新的製造商难以进入市场。

此外，疫苗引发皮疹的增多也可能阻碍带状疱疹疫苗市场的成长。接种疫苗后出现皮疹等不良反应可能会降低人们对疫苗的信心，从而减少需求，最终影响市场的成长。

目录

第一章 引言

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第二章调查方法

  • 资料探勘
  • 二次调查
  • 初步调查
  • 专家建议
  • 品质检查
  • 最终审核
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 观点

第三章执行摘要

  • 全球带状疱疹疫苗市场概况
  • 2024-2030年全球带状疱疹疫苗市场规模预测
  • 带状疱疹疫苗全球市场价值估计与预测（2024-2030）
  • 带状疱疹疫苗全球生态图谱（2022年分享）
  • 竞争分析：漏斗图
  • 带状疱疹疫苗全球市场绝对商机
  • 全球带状疱疹疫苗市场吸引力分析（按地区）
  • 全球带状疱疹疫苗市场吸引力分析（按产品类型）
  • 全球带状疱疹疫苗市场吸引力分析（按疫苗类型）
  • 依年龄层对全球带状疱疹疫苗市场的吸引力分析
  • 全球带状疱疹疫苗市场吸引力分析（按销售管道）
  • 全球带状疱疹疫苗市场（依产品类型）
  • 全球带状疱疹疫苗市场（依疫苗类型）
  • 全球带状疱疹疫苗市场（按年龄层）
  • 全球带状疱疹疫苗市场依销售管道
  • 未来市场机会

第四章 市场展望

  • 全球带状疱疹疫苗市场的变化
  • 带状疱疹疫苗的全球市场前景
  • 市场驱动因素
    • 带状疱疹盛行率不断上升
    • 提高对带状疱疹的认识
  • 市场限制
    • 疫苗高成本
  • 市场趋势
    • 人口老化
  • 市场机会
    • 疫苗技术开发
  • 波特五力分析
    • 新进入者的威胁
    • 替代品的威胁
    • 供应商的议价能力
    • 买家的议价能力
    • 竞争对手之间的竞争强度
  • 宏观经济分析
  • 价值链分析
  • 定价分析
  • 规定
    • 沙乌地阿拉伯食品药物管理局（SFDA）
  • 产品生命线

第五章 依产品类型分類的市场

  • 概述
  • 全球带状疱疹疫苗市场：依产品类型分析基点份额（bps）
  • 佐斯塔瓦克斯
  • 定序
  • 天空之星

第六章 疫苗类型市场

  • 概述
  • 全球带状疱疹疫苗市场：按疫苗类型分類的基点份额（bps）分析
  • 减毒活病毒疫苗
  • 重组疫苗

第七章 分销通路市场

  • 概述
  • 全球带状疱疹疫苗市场：按分销管道分類的基点份额（bps）分析
  • 私人的
  • 民众

第八章 年龄层市场

  • 概述
  • 全球带状疱疹疫苗市场：依年龄层分析Basis Point Share（bps）
  • 50至65岁
  • 65岁或以上
  • 18岁以上，50岁以下

第九章 区域市场

  • 概述
    • 印度
    • 台湾
    • 泰国
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 土耳其
    • 巴西
    • 墨西哥
    • 阿根廷

第十章 竞争格局

  • 概述
  • 竞争场景
  • 市场排名分析
  • 区域足迹
  • 公司在各行业的足迹
  • 王牌矩阵
    • 积极的
    • 前线
    • 新兴
    • 创新者

第十一章 公司简介

  • GLAXOSMITHKLINE PLC.
  • MERCK & CO., INC.
  • SK BIOSCIENCES（SK CHEMICALS）
  • GENEONE LIFE SCIENCE
  • PFIZER
  • CANSINO BIOLOGICS INC.
  • VACCITECH
  • INOVIO PHARMACEUTICALS, INC.
  • CUREVO INC.
Product Code: 35907

Zoster Vaccine Market Valuation - 2026-2032

The rising prevalence of chronic diseases and the aging population are driving the demand for zoster vaccine market. Additionally, the zoster vaccine can be attributed to the increasing awareness regarding the importance of vaccination in helping to prevent shingles caused by the varicella-zoster virus is anticipated to fuel the market to surpass revenue of USD 1.62 Billion valued in 2024 and reach USD 3.47 Billion by 2032.

Also, growing advancements in vaccine technology and the development of new and more effective vaccines are also expected to propel the growth of the zoster vaccine market. The increasing implementation of healthcare policies in developed nations is enabling the market grow at a CAGR of about 10% from 2026 to 2032.

Zoster Vaccine Market: Definition/ Overview

The zoster vaccine, commonly referred to as the shingles vaccine, is a crucial preventive measure against herpes zoster, an ailment triggered by the reactivation of the varicella-zoster virus, which also causes chickenpox. This vaccine contains a weakened form of the virus, stimulating the immune system to produce antibodies that can prevent or mitigate the severity of shingles. Its primary application lies in preventing shingles in individuals aged 50 and older, who are at an increased risk due to age-related decline in immunity. Additionally, the vaccine helps in reducing complications associated with shingles, such as chronic pain and neurological issues.

Currently, there are two main types of zoster vaccines available that are Shingrix and Zostavax and future research is exploring even more effective options with broader applications. The Protection and require fewer doses, potential expansion of recommendations to include younger age groups or those with specific medical conditions, exploration of combination vaccines for simplified immunization schedules, and efforts to enhance global access, particularly in low- and middle-income countries, to alleviate the burden of shingles-related illness on a global scale.

Will Increasing Cases of Herpes Zoster Worldwide Drive the Growth of the Zoster Vaccine Market?

The prevalence of herpes zoster disease is rising globally due to factors such as the aging population, weakened immune systems, and increased prevalence of chronic diseases such as cancer and HIV will drive the growth of the zoster vaccine market

As a result, the demand for zoster vaccine is likely to increase in the coming years as more people become aware of the importance of vaccination to prevent shingles. This presents a significant opportunity for the growth of the zoster vaccine market. For instance, on 25 April 2023, GSK launched the shingles vaccine, (herpes zoster). GSK said the vaccine had 90% efficacy and provided at least 10 years of protection against herpes zoster.

The growing awareness among people about the importance of vaccination to prevent shingles is driving the demand for the zoster vaccine market. The aging population worldwide is also contributing to the growth of the market as older adults are more susceptible to shingles. For instance, according seroprevalence study in Indian subjects showed that by the age of 40 years, more than 90% of the participants had this virus in their bodies and were therefore vulnerable to shingles. For the prevention of shingles and post-herpetic neuralgia, Shingrix vaccine has been approved for adults above 50 years.

Furthermore, advancements in vaccine technology and the development of new and more effective vaccines are expected to boost the growth of the market. All these factors suggest that the zoster vaccine market is poised for steady growth in the coming years.

Will The High Cost of Zoster Vaccine Hamper the Growth of the Zoster Vaccine Market?

Increasing the high cost of the zoster vaccine can be a significant barrier for many people, especially in low-income countries, and it could potentially hamper the growth of the zoster vaccine market. This cost barrier stems from various factors, including the complexities of research and development, manufacturing processes, distribution logistics, and the necessity for multiple doses to ensure effective immunity.

Additionally, healthcare providers and institutions may face financial constraints in purchasing high-cost vaccines like the zoster vaccine, particularly in settings where reimbursement rates are inadequate. This can further limit access to vaccination and reduce overall demand, constraining market growth.

Growing awareness of stringent regulations can indeed pose a challenge to the growth of the zoster vaccine market. The regulatory approval process for vaccines can be lengthy and costly, which can delay the launch of new vaccines and limit their availability. Additionally, regulatory requirements for safety and efficacy can be strict, which can make it difficult for new manufacturers to enter the market.

Furthermore, the increasing occurrence of vaccine rashes can indeed hinder the growth of the zoster vaccine market. When people experience rashes or other adverse reactions after receiving a vaccine, it can lead to a decrease in confidence in the vaccine and reduce demand for it. This can ultimately impact the growth of the market.

Category-Wise Acumens

Will the Rising Utilization of the Shingrix Vaccine Drive the Zoster Vaccine Market?

The rising use of the Shingrix vaccine is expected to drive the zoster vaccine market. Shingrix is a highly effective vaccine for preventing zoster, and it has been shown to provide longer-lasting protection than other available vaccines. This vaccine provides a high level of immunity for at least 7 years after vaccination, as more people become aware of the benefits of Shingrix the demand for the vaccine is expected to increase, which will help to drive growth in the zoster vaccine market.

Additionally, during the forecast period, there will be a rise in demand for these vaccinations due to increasing awareness of the disease's effects and the growing number of countries that have approved Shingrix for use as a vaccine. For instance, GSK announced the shingles vaccine Shingrix in India. This vaccine is recommended for people aged 50 years and above to protect against shingles.

Increasing awareness of the importance of shingles vaccination will drive the zoster vaccine market Companies may invest in marketing efforts to differentiate their products and highlight their efficacy and safety profiles. Additionally, the drive for innovation may lead to the development of new vaccine formulations or delivery methods to better meet the needs of consumers.

The surge in demand for shingles vaccines propels market expansion, prompting vaccine manufacturers to bolster production capacities to satisfy healthcare providers and consumer requirements. This heightened production not only addresses immediate demand but also fosters increased investment in research and development. As revenue streams grow, manufacturers allocate more resources to R&D endeavors, aiming to enhance vaccine efficacy, safety, and accessibility

Increasing demand for technological developments in vaccine formulation, delivery, and production are improving the accessibility, safety, and efficacy of vaccinations. This accelerates the market's growth for zoster vaccines, providing better preventive treatments and enhanced public health results.

Will Increasing Demand for Recombinant Vaccine will Boost the Zoster Vaccine Market?

Recombinant vaccines are produced using genetic engineering techniques, which allows for more precise targeting of the virus or bacteria being targeted. This technology has been used to develop new vaccines, including the Shingrix vaccine for shingles. The growing use of recombinant vaccines offers several advantages over traditional vaccines, including improved safety, efficacy, and ease of production. As a result, they are becoming increasingly popular among healthcare providers and patients. This vaccine contains purified parts of pathogen that are antigenic, or necessary to elicit a protective immune response.

In addition to the benefits of recombinant vaccines, other factors such as the aging population, increasing healthcare expenditure, and rising awareness regarding the importance of preventive healthcare are expected to contribute to the growth of the zoster vaccine market. Aging comes with several health problems such as a weak immune system, which make the old population susceptible to infections like shingles. The increasing geriatric population globally estimated at 3 to 5 cases per 1000 individuals annually is contributing to the growth of the zoster vaccine market and is expected to continue its growth throughout the forecast period.

Country/Region-wise

How the Increasing Prevalence of Chickenpox in North America will Drive the Zoster Vaccine Market?

The rising prevalence of chickenpox in North America boost the zoster vaccine market. Chickenpox and shingles are caused by the same virus, known as the varicella-zoster virus. While chickenpox is a common childhood illness, the virus can remain dormant in the body and reactivate later in life as shingles. Additionally, recommendations for shingles vaccine may be part of the public health response to chickenpox outbreaks, especially for those who are more susceptible due to age or underlying medical issues. For Instance, on 7 September 2022, 21,060 cases of chickenpox were recorded by Mexican health authorities (11,057 males and 10,003 women). This is a significantly higher number than the 8,897 cases reported in 2021, a 137% rise. The likelihood of developing shingles is increased by the high prevalence of chickenpox.

The rising healthcare expenditure in North America has led to a surge in demand for the Zoster vaccine, thereby driving the growth of the market. This vaccine is highly effective in preventing shingles, which is a painful skin rash caused by the reactivation of the varicella-zoster virus.

Rising awareness regarding preventive healthcare will drive the zoster vaccine market. Public health campaigns and a growing focus on preventative measures are making people more aware of the importance of proactive healthcare. This shift in perspective is leading to a greater willingness to get vaccinated against diseases like shingles. People are becoming more informed about the potential complications of shingles, such as PHN, and understand the value of vaccination in preventing this debilitating condition. This growing awareness will likely lead to a significant increase in the demand for zoster vaccines in the coming years.

Will Growing Awareness of Government Vaccine Programs in Asia Pacific Drive the Zoster Vaccine Market?

Growing awareness of government vaccine programs in the Asia-Pacific region is expected to drive the demand for zoster vaccines and contribute to the growth of the market. Many governments in the region have launched vaccination programs to prevent various diseases, including shingles. These programs aim to increase awareness about vaccination and make vaccines more accessible to the population, especially older adults who are more susceptible to shingles.

For example, in Japan, the government has included the zoster vaccine in its national vaccination program for older adults, which covers the cost of the vaccine for eligible individuals. Additionally, in India, the government has launched various vaccination programs to prevent diseases such as hepatitis, influenza, and pneumococcal disease, which are also expected to increase awareness about the importance of vaccination and drive the demand for zoster vaccine.

Changing lifestyles in Asia-Pacific are expected to drive the zoster vaccine market. As people in the region become more health-conscious and adopt healthier lifestyles, the risk of developing shingles may decrease. However, the demand for zoster vaccine is still expected to increase as people become more aware of the importance of vaccination and take preventive measures to protect themselves against the disease.

Furthermore, government initiatives are expected to boost the growth of the market and encourage more manufacturers to invest in the development of new and more effective vaccines for shingles.

Competitive Landscape

The zoster vaccine market, while experiencing promising growth, is a concentrated landscape with a few key players vying for dominance. The zoster vaccine market is dynamic and competitive and will benefit public health. It can lead to the development of more effective, accessible, and affordable vaccines, offering broader protection against shingles and its debilitating complications. The interplay between established players, innovative newcomers, and regulatory bodies will define the future of the zoster vaccine market.

Some of the prominent players operating in the zoster vaccine market include:

  • GSK plc
  • Merck & Co., Inc.
  • Curevo Inc
  • Geneone Life Science
  • SK bioscience

Latest Developments

  • In February 2023, Pfizer Inc. and BioNTech SE launched a phase 1/2 trial to investigate the safety, tolerability, and immunogenicity of their mRNA vaccine candidates against varicella-zoster virus (VZV), which causes shingles, a severe condition referred to as herpes zoster, or HZ
  • In April 2023, GSK launched an anti-shingles vaccine in India. The vaccine is used to prevent herpes zoster and neuralgia in adults aged 50 years old
  • In February 2023, Jiangsu Recbio Technology Co., Ltd completed the first batch of subject enrollment for its adjuvant recombinant shingles vaccine, REC610.

Zoster Vaccine Market, By Category

  • Product Type
  • Zostavax
  • Shingrix
  • SKYZoster
  • Vaccine Type:
  • Recombinant Vaccine
  • Live Attenuated Vaccine
  • Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Age Group:
  • Above 50 to 65 Age
  • Above 65 Age
  • Above 18 to 50 Age
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW
  • 2.11 THOUGHT LEADERSHIP OPINION

3 EXECUTIVE SUMMARY

  • 3.1 GLOBAL ZOSTER VACCINE MARKET OVERVIEW
  • 3.2 GLOBAL ZOSTER VACCINE MARKET ESTIMATES AND FORECAST (USD MILLION), 2024-2030
  • 3.3 GLOBAL ZOSTER VACCINE MARKET VALUE (USD MILLION) ESTIMATES AND FORECAST, 2024-2030
  • 3.4 GLOBAL ZOSTER VACCINE ECOLOGY MAPPING (% SHARE IN 2022)
  • 3.5 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • 3.6 GLOBAL ZOSTER VACCINE MARKET ABSOLUTE MARKET OPPORTUNITY
  • 3.7 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • 3.8 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
  • 3.9 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY VACCINE TYPE
  • 3.10 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY AGE GROUP
  • 3.11 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY SALES CHANNEL
  • 3.12 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE (USD MILLION)
  • 3.13 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE (USD MILLION)
  • 3.14 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP (USD MILLION)
  • 3.15 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL (USD MILLION)
  • 3.16 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

  • 4.1 GLOBAL ZOSTER VACCINE MARKET EVOLUTION
  • 4.2 GLOBAL ZOSTER VACCINE MARKET OUTLOOK
  • 4.3 MARKET DRIVERS
    • 4.3.1 INCREASING PREVALENCE OF HERPES ZOSTER
    • 4.3.2 GROWING AWARENESS ABOUT HERPES ZOSTER
  • 4.4 MARKET RESTRAINTS
    • 4.4.1 HIGH COST OF VACCINES
  • 4.5 MARKET TRENDS
    • 4.5.1 AGEING POPULATION
  • 4.6 MARKET OPPORTUNITY
    • 4.6.1 DEVELOPMENTS IN VACCINE TECHNOLOGY
  • 4.7 PORTER'S FIVE FORCES ANALYSIS
    • 4.7.1 THREAT OF NEW ENTRANTS
    • 4.7.2 THREAT OF SUBSTITUTES
    • 4.7.3 BARGAINING POWER OF SUPPLIERS
    • 4.7.4 BARGAINING POWER OF BUYERS
    • 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 4.8 MACROECONOMIC ANALYSIS
  • 4.9 VALUE CHAIN ANALYSIS
  • 4.10 PRICING ANALYSIS
  • 4.11 REGULATIONS
    • 4.11.1 SAUDI FOOD AND DRUG AUTHORITY (SFDA)
  • 4.12 PRODUCT LIFELINE

5 MARKET, BY PRODUCT TYPE

  • 5.1 OVERVIEW
  • 5.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
  • 5.3 ZOSTAVAX
  • 5.4 SHINGRIX
  • 5.5 SKYZOSTER

6 MARKET, BY VACCINE TYPE

  • 6.1 OVERVIEW
  • 6.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY VACCINE TYPE
  • 6.1 LIVE ATTENUATED VACCINE
  • 6.2 RECOMBINANT VACCINE

7 MARKET, BY SALES CHANNEL

  • 7.1 OVERVIEW
  • 7.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY SALES CHANNEL
  • 7.3 PRIVATE
  • 7.4 PUBLIC

8 MARKET, BY AGE GROUP

  • 8.1 OVERVIEW
  • 8.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY AGE GROUP
  • 8.3 ABOVE 50 TO 65 AGE
  • 8.4 ABOVE 65 AGE
  • 8.5 ABOVE18 TO 50 AGE

9 MARKET, BY GEOGRAPHY

  • 9.1 OVERVIEW
    • 9.1.1 INDIA
    • 9.1.2 TAIWAN
    • 9.1.3 THAILAND
    • 9.1.4 SAUDI ARABIA
    • 9.1.5 UAE
    • 9.1.6 TURKEY
    • 9.1.7 BRAZIL
    • 9.1.8 MEXICO
    • 9.1.9 ARGENTINA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPETITIVE SCENARIO
  • 10.3 COMPANY MARKET RANKING ANALYSIS
  • 10.4 COMPANY REGIONAL FOOTPRINT
  • 10.5 COMPANY INDUSTRY FOOTPRINT
  • 10.6 ACE MATRIX
    • 10.6.1 ACTIVE
    • 10.6.2 CUTTING EDGE
    • 10.6.3 EMERGING
    • 10.6.4 INNOVATORS

11 COMPANY PROFILES

  • 11.1 GLAXOSMITHKLINE PLC.
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 COMPANY INSIGHTS
    • 11.1.3 SEGMENT BREAKDOWN
    • 11.1.4 PRODUCT BENCHMARKING
    • 11.1.5 KEY DEVELOPMENTS
    • 11.1.6 SWOT ANALYSIS
    • 11.1.7 WINNING IMPERATIVES
    • 11.1.8 CURRENT FOCUS & STRATEGIES
    • 11.1.9 THREAT FROM COMPETITION
  • 11.2 MERCK & CO., INC.
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 COMPANY INSIGHTS
    • 11.2.3 SEGMENT BREAKDOWN
    • 11.2.4 PRODUCT BENCHMARKING
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 WINNING IMPERATIVES
    • 11.2.7 CURRENT FOCUS & STRATEGIES
    • 11.2.8 THREAT FROM COMPETITION
  • 11.3 SK BIOSCIENCES (SK CHEMICALS)
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 COMPANY INSIGHTS
    • 11.3.3 PRODUCT BENCHMARKING
    • 11.3.4 SWOT ANALYSIS
    • 11.3.5 WINNING IMPERATIVES
    • 11.3.6 CURRENT FOCUS & STRATEGIES
    • 11.3.7 THREAT FROM COMPETITION
  • 11.4 GENEONE LIFE SCIENCE
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 COMPANY INSIGHTS
    • 11.4.3 PRODUCT BENCHMARKING
  • 11.5 PFIZER
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 COMPANY INSIGHTS
    • 11.5.3 SEGMENT BREAKDOWN
    • 11.5.4 PRODUCT BENCHMARKING
    • 11.5.5 KEY DEVELOPMENTS
  • 11.6 CANSINO BIOLOGICS INC.
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 COMPANY INSIGHTS
    • 11.6.3 SEGMENT BREAKDOWN
    • 11.6.4 PRODUCT BENCHMARKING
  • 11.7 VACCITECH
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 COMPANY INSIGHTS
    • 11.7.3 PRODUCT BENCHMARKING
    • 11.7.4 KEY DEVELOPMENTS
  • 11.8 INOVIO PHARMACEUTICALS, INC.
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 COMPANY INSIGHTS
    • 11.8.3 SEGMENT BREAKDOWN
  • 11.9 CUREVO INC.
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 COMPANY INSIGHTS
    • 11.9.3 PRODUCT BENCHMARKING

LIST OF TABLES

  • TABLE1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 3 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 4 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 5 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 6 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 7 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 8 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
  • TABLE 9 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (THOUSAND DOSES)
  • TABLE10 INDIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE11 INDIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE12 INDIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE13 INDIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE14 INDIA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE15 INDIA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE16 TAIWAN ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE17 TAIWAN ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE18 TAIWAN ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE19 TAIWAN ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 20 TAIWAN ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 21 TAIWAN ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 22 THAILAND ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 23 THAILAND ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 24 THAILAND ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 25 THAILAND ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 26 THAILAND ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 27 THAILAND ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 28 SAUDI ARABIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 29 SAUDI ARABIA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 30 SAUDI ARABIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 31 SAUDI ARABIA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 32 SAUDI ARABIA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 33 SAUDI ARABIA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 34 UAE ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 35 UAE ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 36 UAE ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 37 UAE ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 38 UAE ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 39 UAE ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 40 TURKEY ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 41 TURKEY ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 42 TURKEY ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 43 TURKEY ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 44 TURKEY ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 45 TURKEY ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 46 BRAZIL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 47 BRAZIL ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 48 BRAZIL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 49 BRAZIL ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 50 BRAZIL ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 51 BRAZIL ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 52 MEXICO ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 53 MEXICO ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 54 MEXICO ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 55 MEXICO ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 56 MEXICO ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 57 MEXICO ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 58 ARGENTINA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
  • TABLE 59 ARGENTINA ZOSTER VACCINE MARKET, BY PRODUCT TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 60 ARGENTINA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (USD MILLION)
  • TABLE 61 ARGENTINA ZOSTER VACCINE MARKET, BY VACCINE TYPE, 2021-2030 (THOUSAND DOSES)
  • TABLE 62 ARGENTINA ZOSTER VACCINE MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
  • TABLE 63 ARGENTINA ZOSTER VACCINE MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
  • TABLE 64 COMPANY REGIONAL FOOTPRINT
  • TABLE 65 COMPANY INDUSTRY FOOTPRINT
  • TABLE 66 GLAXOSMITHKLINE PLC.: PRODUCT BENCHMARKING
  • TABLE 67 GLAXOSMITHKLINE PLC.: KEY DEVELOPMENTS
  • TABLE 68 GLAXOSMITHKLINE PLC.: WINNING IMPERATIVES
  • TABLE 69 MERCK & CO., INC.: PRODUCT BENCHMARKING
  • TABLE 70 MERCK & CO., INC.: WINNING IMPERATIVES
  • TABLE 71 SK BIOSCIENCES (SK CHEMICALS): PRODUCT BENCHMARKING
  • TABLE 72 SK BIOSCIENCES (SK CHEMICALS): WINNING IMPERATIVES
  • TABLE 73 GENEONE LIFE SCIENCE: PRODUCT BENCHMARKING
  • TABLE 74 PFIZER: PRODUCT BENCHMARKING
  • TABLE 75 PFIZER: KEY DEVELOPMENTS
  • TABLE 76 CANSINO BIOLOGICS INC.: PRODUCT BENCHMARKING
  • TABLE 77 VACCITECH: PRODUCT BENCHMARKING
  • TABLE 78 VACCITECH: KEY DEVELOPMENTS
  • TABLE 79 CUREVO INC.: PRODUCT BENCHMARKING

LIST OF FIGURES

  • FIGURE1 GLOBAL ZOSTER VACCINE MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 THOUGHT LEADERSHIP OPINION
  • FIGURE 6 SUMMARY
  • FIGURE 7 GLOBAL ZOSTER VACCINE MARKET ESTIMATES AND FORECAST (USD MILLION), 2024-2030
  • FIGURE 8 GLOBAL ZOSTER VACCINE MARKET VALUE (USD MILLION) AND FORECAST, 2024-2030
  • FIGURE 9 GLOBAL ZOSTER VACCINE ECOLOGY MAPPING (% SHARE IN 2022)
  • FIGURE10 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • FIGURE11 GLOBAL ZOSTER VACCINE MARKET ABSOLUTE MARKET OPPORTUNITY
  • FIGURE12 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • FIGURE13 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
  • FIGURE14 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY VACCINE TYPE
  • FIGURE15 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY AGE GROUP
  • FIGURE16 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY SALES CHANNEL
  • FIGURE17 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE (USD MILLION)
  • FIGURE18 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE (USD MILLION)
  • FIGURE19 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP (USD MILLION)
  • FIGURE 20 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL (USD MILLION)
  • FIGURE 21 FUTURE MARKET OPPORTUNITIES
  • FIGURE 22 GLOBAL ZOSTER VACCINE MARKET OUTLOOK
  • FIGURE 23 MARKET DRIVERS IMPACT ANALYSIS
  • FIGURE 24 RESTRAINTS IMPACT ANALYSIS
  • FIGURE 25 KEY TRENDS
  • FIGURE 26 PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 ZOSTER VACCINES MARKET PRICES BY REGION UNIT/DOSE)
  • FIGURE 28 PRODUCT LIFELINE: ELECTRICAL STEEL SHEET MARKET
  • FIGURE 29 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE
  • FIGURE 30 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
  • FIGURE 31 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE
  • FIGURE 32 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY VACCINE TYPE
  • FIGURE 33 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL
  • FIGURE 34 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY SALES CHANNEL
  • FIGURE 35 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP
  • FIGURE 36 GLOBAL ZOSTER VACCINE MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY AGE GROUP
  • FIGURE 37 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
  • FIGURE 38 GLOBAL ZOSTER VACCINE MARKET, BY GEOGRAPHY, 2021-2030 (THOUSAND DOSES)
  • FIGURE 39 INDIA MARKET SNAPSHOT
  • FIGURE 40 TAIWAN MARKET SNAPSHOT
  • FIGURE 41 THAILAND MARKET SNAPSHOT
  • FIGURE 42 SAUDI ARABIA MARKET SNAPSHOT
  • FIGURE 43 UAE MARKET SNAPSHOT
  • FIGURE 44 HERPES ZOSTER INCIDENCE PER ONE MILLION POPULATION, BY AGE, 2018 & 2019
  • FIGURE 45 TURKEY MARKET SNAPSHOT
  • FIGURE 46 NUMBER OF HERPS ZOSTER DIAGNOSES REPORTED IN MARCH -AUGUST (2018-2020)
  • FIGURE 47 BRAZIL MARKET SNAPSHOT
  • FIGURE 48 MEXICO MARKET SNAPSHOT
  • FIGURE 49 ARGENTINA MARKET SNAPSHOT
  • FIGURE 50 KEY STRATEGIC DEVELOPMENTS
  • FIGURE 51 COMPANY MARKET RANKING ANALYSIS
  • FIGURE 52 ACE MATRIC
  • FIGURE 53 GLAXOSMITHKLINE PLC.: COMPANY INSIGHT
  • FIGURE 54 GLAXOSMITHKLINE PLC.: BREAKDOWN
  • FIGURE 55 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS
  • FIGURE 56 MERCK & CO., INC.: COMPANY INSIGHT
  • FIGURE 57 MERCK & CO., INC.: BREAKDOWN
  • FIGURE 58 MERCK & CO., INC.: SWOT ANALYSIS
  • FIGURE 59 SK BIOSCIENCES (SK CHEMICALS): COMPANY INSIGHT
  • FIGURE 60 SK BIOSCIENCES (SK CHEMICALS): SWOT ANALYSIS
  • FIGURE 61 GENEONEE LIFE SCIENCE: COMPANY INSIGHT
  • FIGURE 62 PFIZER: COMPANY INSIGHT
  • FIGURE 63 PFIZER: BREAKDOWN
  • FIGURE 64 CANSINO BIOLOGICS INC.: COMPANY INSIGHT
  • FIGURE 65 CANSINO BIOLOGICS INC.: BREAKDOWN
  • FIGURE 66 VACCITECH: COMPANY INSIGHT
  • FIGURE 67 INOVIO PHARMACEUTICALS, INC.: COMPANY INSIGHT
  • FIGURE 68 INOVIO PHARMACEUTICALS, INC.: BREAKDOWN
  • FIGURE 69 CUREVO INC.: COMPANY INSIGHT